SCHEMBL14737152

SCHEMBL14737152

COc1ccc(-c2cccc3c2CCC3=O)c(OCc2ccc(C(N)=O)cc2)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 1/20 0.48
ATM Q13315 1/20 0.41
MAPT P10636 1/20 0.40
RXRA P19793 1/20 0.40
PARP1 P09874 1/20 0.40
PARP10 Q53GL7 3/20 0.39
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
HDAC8 Q9BY41 2/20 0.37
HDAC4 P56524 1/20 0.37
HDAC2 Q92769 1/20 0.37
MEN1 O00255 1/20 0.36
SMPD1 P17405 2/20 0.36
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2592764 0.91 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDKMT2AMRGPRX4
SCHEMBL2593760 0.91 KDM4E (0.38) ALDH1A1KDM4EHPGDATMMAPT
SCHEMBL7706649 0.89 PARP10 (0.38) ALDH1A1KDM4EHPGDATMMAPT
SCHEMBL2591335 0.88 KDM4E (0.46) ALDH1A1KDM4EHPGDATMMAPT
SCHEMBL2591657 0.88 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDATMMAPT
SCHEMBL14737971 0.85 KMT2A (0.40) ALDH1A1KDM4EATMMAPTRXRA
SCHEMBL2591462 0.84 KDM4E (0.48) ALDH1A1KDM4EHPGD
SCHEMBL2583872 0.83 KDM4E (0.49) ALDH1A1KDM4EHPGDKMT2AHDAC8
SCHEMBL14734816 0.82 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDMAPTKMT2A
SCHEMBL2588509 0.82 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP claimed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US claimed
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A ALDH1A1 824/4885KDM4E 1593/4885HPGD 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.